Inventor · disambiguated record
Robert Shalwitz
Also filed as: SHALWITZ ROBERT · SHALWITZ ROBERT A
30 granted patents·37 pending applications·414 citations·filing 2003–2025
97Inventor score
Files withAERPIO THERAPEUTICS INC36AERPIO PHARMACEUTICALS INC8INVIRSA INC7SHALWITZ ROBERT4GARDNER JOSEPH H3
Top patents by PatentIndex Score
67 records- 0198US9949956B2Compounds, compositions, and methods for preventing metastasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2015·Granted Apr 24, 2018·21 cites·18 claims
- 0298US9174950B2Compounds, compositions, and methods for preventing metastasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2014·Granted Nov 3, 2015·32 cites·20 claims
- 0397US10220048B2Compositions and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2016·Granted Mar 5, 2019·19 cites·13 claims
- 0497US9440963B2Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2014·Granted Sep 13, 2016·35 cites·60 claims
- 0597US9096555B2Methods for treating vascular leak syndromeAERPIO THERAPEUTICS INC·Filed 2012·Granted Aug 4, 2015·32 cites·2 claims
- 0697US8883832B2Compounds, compositions, and methods for preventing metastasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2013·Granted Nov 11, 2014·38 cites·52 claims
- 0797US8569348B2Compounds, compositions, and methods for preventing metastasis of cancer cellsSHALWITZ ROBERT·Filed 2010·Granted Oct 29, 2013·37 cites·15 claims
- 0896US8999325B2Treatment of ocular diseaseAERPIO THERAPEUTICS INC·Filed 2012·Granted Apr 7, 2015·36 cites·18 claims
- 0995US10329357B2Treatment of ocular diseaseAERPIO THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·16 cites·11 claims
- 1095US10150811B2Methods for treating vascular leak syndrome and cancerAERPIO THERAPEUTICS INC·Filed 2017·Granted Dec 11, 2018·15 cites·14 claims
- 1194US10946034B2Methods for the use of 5′-adenosine diphosphate ribose (ADPR)INVIRSA INC·Filed 2019·Granted Mar 16, 2021·5 cites·23 claims
- 1294US8865748B2Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancerSHALWITZ ROBERT·Filed 2012·Granted Oct 21, 2014·28 cites·18 claims
- 1393US11857561B2Methods for the use of 5′-adenosine diphosphate ribose (ADPR)INVIRSA INC·Filed 2021·Granted Jan 2, 2024·2 cites·5 claims
- 1493US9278930B2Methods for increasing the stabilization of hypoxia inducible factor-αAERPIO THERAPEUTICS INC·Filed 2015·Granted Mar 8, 2016·8 cites·13 claims
- 1593US8883774B2Methods for increasing the stabilization of hypoxia inducible factor-1 alphaAERPIO THERAPEUTICS INC·Filed 2013·Granted Nov 11, 2014·12 cites·12 claims
- 1693US8309537B2Compositions and methods for treating colitisGARDNER JOSEPH H·Filed 2010·Granted Nov 13, 2012·17 cites·42 claims
- 1792US8999971B2Methods for increasing the stabilization of hypoxia inducible factor-1 alphaAERPIO THERAPEUTICS INC·Filed 2014·Granted Apr 7, 2015·10 cites·20 claims
- 1891US9045495B2Prolyl hydroxylase inhibitorsGARDNER JOSEPH H·Filed 2013·Granted Jun 2, 2015·10 cites·10 claims
- 1991US8778412B2Methods for increasing the stabilization of hypoxia inducible factor-1 alphaSHALWITZ ROBERT·Filed 2010·Granted Jul 15, 2014·10 cites·10 claims
- 2091US8536181B2Prolyl hydroxylase inhibitorsGARDNER JOSEPH H·Filed 2010·Granted Sep 17, 2013·12 cites·20 claims
- 2190US9540326B2Prolyl hydroxylase inhibitorsAERPIO THERAPEUTICS INC·Filed 2015·Granted Jan 10, 2017·5 cites·12 claims
- 2288US12233083B2Methods for the use of 5′-adenosine diphosphate ribose (ADPR)INVIRSA INC·Filed 2023·Granted Feb 25, 2025·1 cites·34 claims
- 2388US11793826B2Methods for the use of 5′-adenosine diphosphate ribose (ADPR)INVIRSA INC·Filed 2021·Granted Oct 24, 2023·2 cites·25 claims
- 2488US10815300B2Methods for treating vascular leak syndrome and cancerAERPIO PHARMACEUTICALS INC·Filed 2018·Granted Oct 27, 2020·5 cites·11 claims
- 2586US12370209B2Methods for the use of 5′-adenosine diphosphate ribose (ADPR)INVIRSA INC·Filed 2023·Granted Jul 29, 2025·0 cites·20 claims
- 2686US12043664B2Methods for treating vascular leak syndrome and cancerEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Jul 23, 2024·1 cites·13 claims
- 2786US11110112B2Methods for the use of 5'-adenosine diphosphate ribose (ADPR)INVIRSA INC·Filed 2017·Granted Sep 7, 2021·4 cites·2 claims
- 2882US12152023B2Compositions, formulations and methods for treating ocular diseasesEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Nov 26, 2024·0 cites·18 claims
- 2980US2022185778A1Prolyl hydroxylase inhibitorsAERPIO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3078US2020207730A1Methods for treating vascular leak syndromeAERPIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3173US2020361926A1Compositions, formulations and methods for treating ocular diseasesAERPIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3272US2018237429A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3372US2018237430A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3472US2018237431A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3571US2020277267A1Methods for treating vascular leak syndromeAERPIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3670US10562854B2Prolyl hydroxylase inhibitorsAERPIO THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·0 cites·13 claims
- 3770US2015050277A1Compositions and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3869US11857543B2Compositions and methods for treating anemiaAKEBIA THERAPEUTICS INC·Filed 2014·Granted Jan 2, 2024·1 cites·30 claims
- 3969US2020108080A1Compositions and methods for treating ocular diseasesAERPIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4069US2020009115A1Compositions and methods for treating ocular edema, neovascularization and related diseasesAERPIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4169US2018022741A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4269US2022016086A1Compositions and methods for treating ocular edema, neovascularization and related diseasesAERPIO PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4368US2020231703A1Treatment of ocular diseaseAERPIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4468US2019076405A1Compounds, compositions, and methods for preventing metasasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4568US2018251457A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4667US2016220540A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4767US2025161343A1Methods for the use of 5'-adenosine diphosphate ribose (adpr)INVIRSA INC·Filed 2025·Application pending·0 cites
- 4866US2019231799A1Compositions and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4965US2017298019A1Prolyl hydroxylase inhibitorsAERPIO THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 5065US2020010565A1Treatment of ocular diseaseAERPIO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Robert Shalwitz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →